A Pilot Study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)

Trial Profile

A Pilot Study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Drug hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2018.
    • 25 Oct 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
    • 24 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top